Up to 85% of gastrointestinal stromal tumors (GIST) harbor mutually exclusive mutations in the KIT or the PDGFRA gene. Among others, known as wild type GIST, succinate dehydrogenase (SDH)-deficient tumors develop due to genetic or epigenetic alterations in any of four SDH genes. Herein, we present a unique case of SDH-deficient GIST with an unusual heterogeneous SDHA and SDHB staining pattern and mutations detected in the SDHA and KIT gene. A 50-year-old patient presented with a 5 cm large gastric tumor with a multinodular/plexiform growth pattern, mixed epithelioid and spindle cell morphology, and focal pronounced nuclear atypia with hyperchromasia and high mitotic activity. Immunohistochemically, CD117 and DOG-1 were positive. SDHB and SDHA stains showed loss of expression in some of the nodules, whereas others presented with an unusually weak patchy positivity. Molecular analysis revealed a point mutation in exon 5 of the SDHA gene and a mutation in exon 11 of the KIT gene. We hypothesize that based on the allele frequency of SDHA and KIT mutations the tumor is best regarded as SDH-deficient GIST in which the SDHA mutation represents the most likely driver mutation. The identified KIT mutation raises the distinct possibility that the KIT mutation is a secondary event reflecting clonal evolution. This is the first case of a treatment naïve GIST harboring a somatic SDHA and a KIT mutation, challenging the dogma that oncogenic mutations in treatment naïve GIST are mutually exclusive.
| INTRODUCTION
Gastrointestinal stromal tumor (GIST) is the most common mesenchymal neoplasm of the gastrointestinal tract with an annual incidence of approximately 10-15 cases per million. 1 It usually presents sporadically in older adults (median age 60-65 years) with no gender predilection. GISTs occur throughout the gastrointestinal tract, but most commonly affect the stomach and the small intestine. Up to 85% of GISTs harbor mutually exclusive mutations in KIT or PDGFRA. 2, 3 These mutations are responsible for upregulation of crucial signaling pathways including MAPK and PI3K-AKT. Most KIT/PDGFRA mutated GISTs respond to the RTK inhibitor imatinib; however, treatment response is mainly depending on tumor genotype. 4, 5 Tumors devoid of KIT and PDGFRA mutations are known as RTKwild type (WT) GISTs. Over the last years, it became apparent that the so-called "WT-GIST group" is quite heterogeneous with regards to clinical phenotype and molecular characteristics. 6 Based on recent advances in molecular pathology, GISTs can be sub-classified in an SDH-competent and an SDH-deficient group, irrespective of whether they are sporadic or familial/genetic.
SDH is an enzyme complex located in the inner mitochondrial membrane and is composed of four subunits (SDHA-D) mapping to 5p15.33, 1p36.13, 1q23.3, and 11q23.1, respectively. The SDH complex connects the oxidation of succinate to fumarate in the Krebs cycle to the reduction of coenzyme Q in the mitochondrial electron transport chain. 7 Genetic or epigenetic alterations of any of the four SDH genes cause destabilization of the SDH-complex and result in accumulation of succinate and activation of cellular pathways leading to increased angiogenesis and cellular proliferation. 7 Destabilization of any of the SDH subunits can be demonstrated by immunohistochemistry, based on the loss of SDHB expression.
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The SDH-competent GISTs include tumors with KIT, PDGFRA, NF1, and BRAF mutations as well as tumors with rare described mutations in ARID1A, ARID1B, CBL, FGFR1, NRAS, HRAS, KRAS, MAX, MEN1, and PIK3CA and novel gene fusions, like KIT-PDGFRA and ETV6-NTRK3.
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In contrast, the SDH-deficient GIST group includes the majority of pediatric GISTs, some sporadic adult/young adult cases, and rare syn- Herein, we report a case of imatinib naïve SDHB-deficient GIST with an unusual immunohistochemical expression profile for SDHA and SDHB and unique molecular findings. 
| PATIENT AND METHODS

| Immunohistochemical analysis
| Targeted next-generation sequencing
Mutational analysis was performed using next-generation sequencing 
| Sanger sequencing
Fifty nanograms of DNA were used for PCR amplification using primers KIT Ex11 fwd 5 0 -TGTTCTCTCTCCAGAGTGCTCTAAT-3 0 and KIT Ex11 rev 5 0 -AAACAAAGGAAGCCACTGGA-3 0 . Amplified PCR products were subjected to Sanger sequencing reaction using BigDye terminator v1.1 Kit (Thermo Fischer, Waltham, MA). Sequences were analyzed using SeqMan Pro Software (DNASTAR) and the 3500
Genetic Analyser (Thermo Fisher). 
| Patient
| DISCUSSION
Up to 85% of GISTs harbor mutually exclusive mutations in the KIT or PDGFRA gene. 2, 3 Based on the underlining genotype, the majority of these tumors respond to treatment with imatinib or second-line treatment with sunitinib or regorafenib. 4, 5, 22, 23 However, almost half of RTK-WT GISTs demonstrate deficiency of the tumor suppressor complex SDH as a distinct alternative mechanism of oncogenesis. Large studies analyzing the SDH status using immunohistochemistry for the SDHB subunit supported the notion that SDH deficiency is in general mutually exclusive to other known oncogenic mechanisms.
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The most extensive series investigated 756 gastric GIST by SDHB immunohistochemistry and identified 66 SDHB deficient GIST, whereas all 378 non-gastric GISTs were found to be SDHB-competent. 6 Heterogeneity of the staining pattern for SDHB was not reported, and staining was performed on a tissue microarray where individual cores might not SDHA mutations in GIST and can, therefore, be used to select patients with SDH-deficient GIST for further molecular analysis. 19, 20 In the English literature, only single-case reports exist demonstrating an SDH-deficient GIST with an RTK mutation. 24 This finding, however, is mainly associated with germline SDH mutations. However, a very well-documented recent case reported by Belinsky et al.
described oncogenic somatic mutations in PDGFRA and SDHB in a metastatic GIST after treatment with several RTKs. Based on the allele frequency of SDHA and KIT mutations, our tumor is best defined as SDH-deficient GIST in which SDH loss is most likely the oncogenic driver. Furthermore, the identified convincing KIT mutation in a small allele fraction raises the distinct possibility that the KIT mutation is a second event reflecting a clonal evolution. Although there is the dogma that oncogenic mutations in GIST are mutually exclusive, there is good evidence that there are well-documented exceptions to this rule.
| CONCLUSION
To the best of our knowledge, this is the first case of a treatment naïve GIST harboring a somatic SDHA mutation best regarded as a potential driver mutation in addition to a somatic KIT mutation explained as a second event reflecting a clonal evolution. This case, together with another recently reported case with SDHB and PDGFRA D842V mutations, challenges the dogma that oncogenic mutations in GIST are mutually exclusive. Expanded molecular testing in the era of NGS may be of diagnostic and therapeutic value and may be the rational for including patients into treatment trials based on the molecular landscape of tumors.
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